Skip to main content

Table 4 Median total 20-item CP-PACIC scale scores by patient respondent characteristic

From: Adaptation and validation of the patient assessment of chronic illness care in United States community pharmacies

Characteristic

n

Median total CP-PACIC scale score (IQR)

P-value

Respondent group typea

546

–––––––––

 < .001***

  In-person

223

29 (36.0)

 

  Online

323

8 (12.0)

 

Age (years)b

541

–––––––––

.018*

  Sexa

540

–––––––––

 < .001***

  Male

137

29 (39.0)

 

  Female

403

11 (19.0)

 

Ethnicitya

506

–––––––––

.729

  Not Hispanic/Latino

497

12 (27)

 

  Hispanic or Latino

9

20 (26)

 

Racec,d

522

–––––––––

.243

  White

444

12 (25.8)

 

  Black or African American

65

16 (33.5)

 

Other

13

23 (36.0)

 

  Educationa

538

–––––––––

 < .001***

  No college

107

29 (38.0)

 

  At least some college

431

11 (22.0)

 

Tobacco use statusa

539

–––––––––

.991

  Never or former user

459

12 (27.0)

 

  Current user

80

11 (32.5)

 

  Health conditions

   

Diabetes a

544

–––––––––

.205

  No

425

12 (26.5)

 

  Yes

119

15 (32.0)

 

Coronary artery disease/heart disease a

545

–––––––––

.006**

  No

502

12 (26.0)

 

  Yes

43

25 (39.0)

 

Chronic pain a

544

–––––––––

.102

  No

401

13 (26.0)

 

  Yes

143

10 (29.0)

 

Heart failure a

545

–––––––––

.146

  No

533

12 (27.0)

 

  Yes

12

40 (53.3)

 

COPD (bronchitis/emphysema) a

545

–––––––––

.176

  No

527

12 (27.0)

 

  Yes

18

22.5 (34.5)

 

Osteoporosis a

545

–––––––––

.213

  No

492

12 (30.0)

 

  Yes

53

12 (17.5)

 

High blood pressure a

545

–––––––––

.125

  No

281

12 (23.5)

 

  Yes

264

14 (30.0)

 

Asthma a

545

–––––––––

.944

  No

453

13 (27.0)

 

  Yes

92

11.5 (29.8)

 

High cholesterol a

545

–––––––––

.638

  No

392

13 (25.0)

 

  Yes

153

11 (32.0)

 

Arthritis a

545

–––––––––

.004**

  No

387

13 (31.0)

 

  Yes

158

10 (21.3)

 

Kidney disease a

545

–––––––––

.254

  No

513

12 (27.0)

 

  Yes

32

17 (37.0)

 

Depression a

545

–––––––––

 < .001***

   No

366

15 (31.0)

 

  Yes

179

9 (18.0)

 

Other a,e

545

–––––––––

 < .001***

  No

350

16 (32.5)

 

  Yes

195

9 (18.0)

 

Pharmacy services receiveda,f

511

–––––––––

 < .001***

  None

386

10 (20.0)

 

  One or more service

125

29 (39.0)

 

Number of prescription medicationsa

540

–––––––––

.669

  Less than three medications

124

11.5 (22.5)

 

  Three or more medications

416

12 (29.5)

 

Frequency of pharmacy visitsa

536

–––––––––

.225

  Less than once a month

101

11 (17.5)

 

  At least once a month

435

13 (30.0)

 

Type of community pharmacy used for prescription medication(s), n (%)c,g

539

–––––––––

 < .001***

  Independently-owned

64

35 (43.0)

 

  Chain

212

8 (16.0)

 

  Grocery store-based pharmacy

113

20 (28.5)

 

  Mass merchandiser

70

8 (15.0)

 

  Health system/hospital outpatient

80

18 (30.0)

 
  1. Abbreviations: COPD Chronic obstructive pulmonary disease, CP-PACIC Community Pharmacy-Patient Assessment of Chronic Illness Care, IQR interquartile range
  2. *** p ≤ 0.001; ** p ≤ 0.01; * p < 0 .05
  3. aGroup differences computed via Mann–Whitney U tests
  4. bRelationship between age and CP-PACIC scores was examined via Spearman’s Correlation tests, r s = .102
  5. cGroup differences computed via Kruskal–Wallis tests, post-hoc pairwise tests performed when median total CP-PACIC scale scores were significantly different. Significance values were adjusted by Bonferroni correction for multiple comparisons
  6. dRace categorized as follows: White (identified as White only), Black or African American (identified as Black or African American OR Black or African American and another race), Other (identified as American Indian, Native Hawaiian/Pacific Islander, or any other combination of races excluding Black)
  7. eThe 10 most frequently reported “other” health conditions included anxiety, attention deficit disorder/attention deficit hyperactivity disorder, autoimmune disorders, cancer, epilepsy, fibromyalgia, gastrointestinal disorders, polycystic ovary syndrome, sleeping disorders, thyroid disorders
  8. f “Not sure” responses were treated as missing data and were not included in analysis
  9. gChain vs. mass merchandiser p = 1.000, Chain vs. independent, grocery, or health system p < .001***, Mass merchandiser vs. grocery p = .012*, Mass merchandiser vs. health system p = .023*, Mass merchandiser vs. independent p < .001***, Grocery vs. health system p = 1.000, Grocery vs. independent p = .041*, Health system vs. independent p = .083